Robert G Miller

Summary

Affiliation: California Pacific Medical Center
Country: USA

Publications

  1. ncbi request reprint A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis
    Michelle Mendoza
    Forbes Norris MDA ALS Research Center, San Francisco, CA 94115, USA
    Amyotroph Lateral Scler 8:106-11. 2007
  2. doi request reprint Hope in palliative care: from narcissism to self-transcendence in amyotrophic lateral sclerosis
    Joanna H Fanos
    Department of Pediatrics, Dartmouth Medical School, Dartmouth Hitchcock Medical Center Lebanon, New Hampshire 03756, USA
    J Palliat Med 11:470-5. 2008
  3. doi request reprint Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    Robert G Miller
    Forbes Norris ALS Research Center, California PacificMedical Center, San Francisco, USA
    Cochrane Database Syst Rev 3:CD001447. 2012
  4. ncbi request reprint Phase II/III randomized trial of TCH346 in patients with ALS
    R Miller
    California Pacific Medical Center, San Francisco, CA 94115, USA
    Neurology 69:776-84. 2007
  5. pmc Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design
    R G Miller
    California Pacific Medical Center, San Francisco, CA, USA
    Neurology 77:973-9. 2011
  6. ncbi request reprint Neuromuscular diseases: therapeutic advances
    Robert G Miller
    California Pacific Medical Center, 2324 Sacramento Street, San Francisco, CA 94115, USA
    Lancet Neurol 7:12-4. 2008
  7. doi request reprint Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database
    Robert G Miller
    Forbes Norris MDA ALS Research Center, California Pacific Medical Center 94115, San Francisco, CA, USA
    Ann Neurol 65:S24-8. 2009
  8. pmc Systemic immune system alterations in early stages of Alzheimer's disease
    Rongzhen Zhang
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Neuroimmunol 256:38-42. 2013
  9. ncbi request reprint MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS)
    Rongzhen Zhang
    University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Neuroimmunol 179:87-93. 2006
  10. pmc Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS)
    Rongzhen Zhang
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Neuroimmunol 230:114-23. 2011

Collaborators

Detail Information

Publications32

  1. ncbi request reprint A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis
    Michelle Mendoza
    Forbes Norris MDA ALS Research Center, San Francisco, CA 94115, USA
    Amyotroph Lateral Scler 8:106-11. 2007
    ..For patients with clinical signs and symptoms needing treatment with NIV, a MIP< -60 cm H(2)O allows US clinicians to obtain non-invasive ventilatory support for patients earlier than if using the FVC criterion alone...
  2. doi request reprint Hope in palliative care: from narcissism to self-transcendence in amyotrophic lateral sclerosis
    Joanna H Fanos
    Department of Pediatrics, Dartmouth Medical School, Dartmouth Hitchcock Medical Center Lebanon, New Hampshire 03756, USA
    J Palliat Med 11:470-5. 2008
    ..Our research explored the meaning of hope in individuals with ALS...
  3. doi request reprint Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    Robert G Miller
    Forbes Norris ALS Research Center, California PacificMedical Center, San Francisco, USA
    Cochrane Database Syst Rev 3:CD001447. 2012
    ..Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy...
  4. ncbi request reprint Phase II/III randomized trial of TCH346 in patients with ALS
    R Miller
    California Pacific Medical Center, San Francisco, CA 94115, USA
    Neurology 69:776-84. 2007
    ..Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS...
  5. pmc Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design
    R G Miller
    California Pacific Medical Center, San Francisco, CA, USA
    Neurology 77:973-9. 2011
    ..To use a historical placebo control design to determine whether lithium carbonate slows progression of amyotrophic lateral sclerosis (ALS)...
  6. ncbi request reprint Neuromuscular diseases: therapeutic advances
    Robert G Miller
    California Pacific Medical Center, 2324 Sacramento Street, San Francisco, CA 94115, USA
    Lancet Neurol 7:12-4. 2008
  7. doi request reprint Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database
    Robert G Miller
    Forbes Norris MDA ALS Research Center, California Pacific Medical Center 94115, San Francisco, CA, USA
    Ann Neurol 65:S24-8. 2009
    ..To examine the care of patients with ALS following the publication of the standardized recommendations for the management of patients with amyotrophic lateral sclerosis (ALS) published in 1999 by the American Academy of Neurology...
  8. pmc Systemic immune system alterations in early stages of Alzheimer's disease
    Rongzhen Zhang
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Neuroimmunol 256:38-42. 2013
    ..These findings suggest that AD pathogenesis may be influenced by systemic immunologic dysfunction and provides potential immunologic targets for therapeutic intervention...
  9. ncbi request reprint MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS)
    Rongzhen Zhang
    University of California, San Francisco, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Neuroimmunol 179:87-93. 2006
    ..Defective monocyte/macrophages may play an active role in sALS...
  10. pmc Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS)
    Rongzhen Zhang
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Neuroimmunol 230:114-23. 2011
    ..Similar patterns of gene expression were reproduced in LPS stimulated PBMCs from healthy controls. These data suggest that chronic monocyte/macrophage activation may be through LPS/TLR4-signaling pathways in ALS...
  11. pmc Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS)
    Rongzhen Zhang
    University of California, San Francisco, San Francisco, CA 94110, USA
    J Neuroimmunol 206:121-4. 2009
    ..These data suggest that systemic LPS levels and activated monocyte/macrophages may play significant roles in the pathogenesis of sALS...
  12. ncbi request reprint Measurement of strength: summary
    Robert G Miller
    California Pacific Medical Center, San Francisco, CA, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 3:S51-4. 2002
  13. ncbi request reprint ALS trial design: expectation and reality
    Robert G Miller
    California Pacific Medical Center, San Francisco, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:52-4. 2004
  14. ncbi request reprint Improving efficiency of ALS clinical trials using lead-in designs
    Dan H Moore
    Research Institute CPMC, San Francisco, CA 94115, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:57-60. 2004
    ..A sample size reduction of 70% can be realized with variable lead-in compared to a parallel design...
  15. ncbi request reprint Role of fatigue in limiting physical activities in humans with neuromuscular diseases
    Robert G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, California 94115, USA
    Am J Phys Med Rehabil 81:S99-107. 2002
    ..Examples of both central and peripheral fatigue in various neuromuscular diseases and other disorders are presented, including metabolic myopathy, chronic fatigue syndrome, postpolio syndrome, and amyotrophic lateral sclerosis...
  16. ncbi request reprint Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS)
    Rongzhen Zhang
    University of California, San Francisco, San Francisco General Hospital, 995 Potrero Avenue, Building 80, Ward 84, Box 0874, San Francisco, CA 94110, USA
    J Neuroimmunol 159:215-24. 2005
    ..These data are consistent with a disease model previously suggested for AD, wherein systemic immunologic activation plays an active role in sALS...
  17. pmc Gray matter perfusion correlates with disease severity in ALS
    Randall R Rule
    4150 Clement Street 114Q, San Francisco, CA 94121, USA
    Neurology 74:821-7. 2010
    ..The presence of such a relationship would indicate a possible role for ASL perfusion as a marker of disease severity and upper motor neuron involvement in ALS...
  18. pmc Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis
    Arie Gruzman
    Bioconformatics Laboratory and Department of Neuroscience, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
    Proc Natl Acad Sci U S A 104:12524-9. 2007
    ..Our results identify a shared molecular event involving a known target gene and suggest a common step in the pathogenesis between SALS and FALS...
  19. ncbi request reprint "You have shown me my end": attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis
    Joanna H Fanos
    Research Institute and Department of Pediatrics, California Pacific Medical Center, San Francisco, California 94115, USA
    Am J Med Genet A 129:248-53. 2004
    ....
  20. ncbi request reprint Classical and emergent measures for clinical trials in ALS
    Robert G Miller
    San Francisco, CA, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 3:S1-2. 2002
  21. ncbi request reprint Fatigue and therapeutic exercise
    Robert G Miller
    Department of Neurosciences, California Pacific Medical Center, 2324 Sacramento Street, 111 San Francisco, CA 94115, USA
    J Neurol Sci 242:37-41. 2006
    ..In this paper, we review recent studies of fatigue in common neurologic conditions and discuss therapeutic interventions. In particular, the role of therapeutic exercise is examined in both health and disease...
  22. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
  23. ncbi request reprint Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial
    P Nigel Leigh
    Department of Neurology, Institute of Psychiatry, London, UK
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:84-98. 2004
    ....
  24. ncbi request reprint Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Gregory T Carter
    Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Center, University of Washington School of Medicine, Seattle, WA 98195, USA
    IDrugs 6:147-53. 2003
    ..We indicate current and future directions in research and clinical trials, and also argue that a logical next step for clinical trials in ALS should be combination drug treatment...
  25. doi request reprint Drug therapy in amyotrophic lateral sclerosis
    B Jane Distad
    Department of Neurology, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Phys Med Rehabil Clin N Am 19:633-51, xi-xii. 2008
    ..The authors review the current understanding of the pathogenic mechanisms of ALS and approaches to treating the disease...
  26. ncbi request reprint ALSFRS-R
    Paul H Gordon
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:90-3. 2004
    ..Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function...
  27. ncbi request reprint Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007
    ..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)...
  28. ncbi request reprint Whole-genome analysis of sporadic amyotrophic lateral sclerosis
    Travis Dunckley
    Translational Genomics Research Inst, Phoenix, AZ 85004, USA
    N Engl J Med 357:775-88. 2007
    ..Approximately 90% of persons with amyotrophic lateral sclerosis (ALS) have the sporadic form, which may be caused by the interaction of multiple environmental factors and previously unknown genes...
  29. ncbi request reprint Promoting excellence in end-of-life care in ALS
    Hiroshi Mitsumoto
    The Elenor and Lou Gehrig MDA ALS Research Center, Columbia University Neurological Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:145-54. 2005
    ..Several public policy changes that will improve coverage for medical care, hospice, and caregiver costs are also reviewed. More clinical evidence is needed on how to provide optimal end-of-life care specifically in ALS...
  30. ncbi request reprint Detecting neurobehavioral changes in amyotrophic lateral sclerosis
    Alison B Grossman
    Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Amyotroph Lateral Scler 8:56-61. 2007
    ..The FrsBe is useful for detecting behavioral change and abnormalities in patients with ALS...
  31. ncbi request reprint NIPPV: a treatment for ALS whose time has come
    Terry D Heiman-Patterson
    Neurology 67:736-7. 2006
  32. ncbi request reprint Factors correlated with NPPV use in ALS
    Carlayne E Jackson
    University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Amyotroph Lateral Scler 7:80-5. 2006
    ..The findings may be useful in designing prospective studies to examine the factors which might explain the underutilization of NPPV and the optimal use of this treatment...